Ignite Creation Date:
2025-12-25 @ 12:37 AM
Ignite Modification Date:
2026-02-25 @ 5:43 PM
Study NCT ID:
NCT01653067
Status:
UNKNOWN
Last Update Posted:
2016-10-27
First Post:
2012-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Sponsor:
Mathias Witzens-Harig
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Diffuse Large B-Cell Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Non Hodgkin´s Lymphoma | View |
| None | Diffuse Large B-Cell Lymphoma | View |
| None | Aggressive Lymphoma | View |
| None | Aggressive Non Hodgkin´s Lymphoma | View |
| None | NHL | View |
| None | aNHL | View |
| None | Temsirolimus | View |
| None | Torisel | View |
| None | Relapsed Non Hodgkin´s Lymphoma | View |
| None | Relapsed Diffuse Large B-Cell Lymphoma | View |
| None | aggressive NHL | View |
| None | B-NHL | View |
| None | aggressive B-NHL | View |